ARID1A and neuroendocrine carcinoma: This patient is disease-free 28 months after diagnosis, which would agree with the NEC-like SMARCA4/ARID1A enriched group of SNUC tumors, which are believed to derive from diffuse neuroendocrine cells and harbor a more favorable prognosis with a 5-year OS of 68% [44].